Complementary target RNA

Complementary target RNA is a generic term referring to the specific ribonucleic acid sequence—typically a messenger RNA (mRNA) or a non-coding RNA—that is targeted by nucleic acid-based therapeutics through Watson-Crick base pairing [1]. This target is not a single biological entity but rather a class of targets defined by their sequence complementarity to drugs such as antisense oligonucleotides (ASOs), small interfering RNAs (siRNAs), and microRNA mimics [2]. The biological function of these targets involves the transfer of genetic information or the regulation of gene expression; by binding to them, drugs can induce RNA degradation via enzymes like RNase H or the RNA-induced silencing complex (RISC), or they can physically block translation or modify splicing patterns [1,3]. This therapeutic strategy is employed across a wide range of diseases, including rare genetic disorders, cancers, and viral infections, particularly for proteins that are difficult to target with traditional small molecules [2]. Key safety considerations include off-target effects where the drug binds to unintended RNA sequences and the potential for the synthetic oligonucleotides to trigger innate immune responses [1]. [1] Crooke, S. T., et al. (2018). RNA-Targeted Therapeutics. Cell Metabolism. [2] Setten, R. L., et al. (2019). The current state and future directions of RNAi-based therapeutics. Nature Reviews Drug Discovery. [3] Watts, J. K., & Corey, D. R. (2012). Silencing disease genes in the laboratory and the clinic. Journal of Pathology.

Other names

Target RNASense RNA strandmRNA targetRNA transcriptTherapeutic RNA target

Binding via Watson-Crick base pairing to facilitate RNA degradation (e.g., via RNase H or RISC), translational blockade, or splice modulation.